Drugs / RNA MCTI CIMATEC HDT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05542693 | Jan → Mar 2023 | COVID-19 | Azidus Brasil | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNA MCTI CIMATEC HDT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05542693 ↗ |
| Known as | MCTI-CIMATEC-HDT RNA | “Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)” NCT05542693 ↗ |
| Modality | Vaccine | “Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine” NCT05542693 ↗ |
| Route | Intramuscular | “Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine” NCT05542693 ↗ |